Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia

British Journal of Haematology

Volumn 150, Issue 3, 2010, Pages 303-312

  Santos, Fabio P S ^a   Kantarjian, Hagop ^a   Fava, Carmen ^a   O'Brien, Susan ^a   Garcia Manero, Guillermo ^a   Ravandi, Farhad ^a   Wierda, William ^a   Thomas, Deborah ^a   Shan, Jianquin ^a   Cortes, Jorge ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

chronic myeloid leukaemia; dasatinib; dose intensity; dose reduction; nilotinib; treatment interruption

Indexed keywords

DASATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIZZINESS; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERAMYLASEMIA; HYPERBILIRUBINEMIA; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLEURA EFFUSION; PRIORITY JOURNAL; RASH; SIDE EFFECT; SURVIVAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; SURVIVAL ANALYSIS; THIAZOLES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77954612906     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08245.x     Document Type: Article

References (33)

1. Baccarani, M., Saglio, G., Goldman, J., Hochhaus, A., Simonsson, B., Appelbaum, F., Apperley, J., Cervantes, F., Cortes, J., Deininger, M., Gratwohl, A., Guilhot, F., Horowitz, M., Hughes, T., Kantarjian, H., Larson, R., Niederwieser, D., Silver, R. Hehlmann, R. (2006) Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 108, 1809 1820.
2. Baccarani, M., Rosti, G., Castagnetti, F., Haznedaroglu, I., Porkka, K., Abruzzese, E., Alimena, G., Ehrencrona, H., Hjorth-Hansen, H., Kairisto, V., Levato, L., Martinelli, G., Nagler, A., Lanng Nielsen, J., Ozbek, U., Palandri, F., Palmieri, F., Pane, F., Rege-Cambrin, G., Russo, D., Specchia, G., Testoni, N., Weiss-Bjerrum, O., Saglio, G. Simonsson, B. (2009) Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood, 113, 4497 4504.
3. Cortes, J., Kim, D.W., Raffoux, E., Martinelli, G., Ritchie, E., Roy, L., Coutre, S., Corm, S., Hamerschlak, N., Tang, J.L., Hochhaus, A., Khoury, H.J., Brummendorf, T.H., Michallet, M., Rege-Cambrin, G., Gambacorti-Passerini, C., Radich, J.P., Ernst, T., Zhu, C., Van Tornout, J.M. Talpaz, M. (2008a) Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia, 22, 2176 2183.
4. Cortes, J., Baccarani, M., Guilhot, F., Druker, B.J., Branford, S., Kim, D.-W., Pane, F., Rudoltz, M., Yu, R., Collins, L., Krahnke, T., Radich, J.P. Hughes, T.P. (2008b) A Phase III, randomized, open-label study of 400 mg versus 800 mg of imatinib mesylate (IM) in patients (pts) with newly diagnosed, previously untreated chronic Myeloid leukemia in chronic phase (CML-CP) using molecular endpoints: 1-year results of TOPS (tyrosine kinase inhibitor optimization and selectivity) study. Blood, 112. Abstract 335.
5. le Coutre, P., Ottmann, O.G., Giles, F., Kim, D.W., Cortes, J., Gattermann, N., Apperley, J.F., Larson, R.A., Abruzzese, E., O'Brien, S.G., Kuliczkowski, K., Hochhaus, A., Mahon, F.X., Saglio, G., Gobbi, M., Kwong, Y.L., Baccarani, M., Hughes, T., Martinelli, G., Radich, J.P., Zheng, M., Shou, Y. Kantarjian, H. (2008) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood, 111, 1834 1839.
6. Cox, D. (1972) Regression models and life tables. Journal of the Royal Statistical Society Series B (Methodological), 34, 187 202.
7. Druker, B.J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G.M., Fanning, S., Zimmermann, J. Lydon, N.B. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Medicine, 2, 561 566.
8. Golemovic, M., Verstovsek, S., Giles, F., Cortes, J., Manshouri, T., Manley, P.W., Mestan, J., Dugan, M., Alland, L., Griffin, J.D., Arlinghaus, R.B., Sun, T., Kantarjian, H. Beran, M. (2005) AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clinical Cancer Research, 11, 4941 4947.
9. Guilhot, F., Apperley, J., Kim, D.W., Bullorsky, E.O., Baccarani, M., Roboz, G.J., Amadori, S., de Souza, C.A., Lipton, J.H., Hochhaus, A., Heim, D., Larson, R.A., Branford, S., Muller, M.C., Agarwal, P., Gollerkeri, A. Talpaz, M. (2007) Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood, 109, 4143 4150. (Pubitemid 46743375)
10. Guilhot, F., Hughes, T.P., Cortes, J., Wang, Y., Hayes, M., Gichangi, A., Druker, B.J. Baccarani, M. (2008) Imatinib (IM) pharmacokinetic (PK) exposure and its correlation with clinical outcome in patients with chronic-phase chronic myeloid leukemia (CML-CP) for 400 mg and 800 mg daily doses (tyrosine kinase dose optimization study [TOPS]) [abstract]. Blood, 112. Abstract 447.
11. Hiwase, D.K., Saunders, V., Hewett, D., Frede, A., Zrim, S., Dang, P., Eadie, L., To, L.B., Melo, J., Kumar, S., Hughes, T.P. White, D.L. (2008) Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clinical Cancer Research, 14, 3881 3888.
12. Hochhaus, A., Baccarani, M., Deininger, M., Apperley, J.F., Lipton, J.H., Goldberg, S.L., Corm, S., Shah, N.P., Cervantes, F., Silver, R.T., Niederwieser, D., Stone, R.M., Dombret, H., Larson, R.A., Roy, L., Hughes, T., Muller, M.C., Ezzeddine, R., Countouriotis, A.M. Kantarjian, H.M. (2008) Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia, 22, 1200 1206.
13. Hughes, T.P., Branford, S., White, D.L., Reynolds, J., Koelmeyer, R., Seymour, J.F., Taylor, K., Arthur, C., Schwarer, A., Morton, J., Cooney, J., Leahy, M.F., Rowlings, P., Catalano, J., Hertzberg, M., Filshie, R., Mills, A.K., Fay, K., Durrant, S., Januszewicz, H., Joske, D., Underhill, C., Dunkley, S., Lynch, K. Grigg, A. (2008) Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood, 112, 3965 3973.
14. Jain, N., Kantarjian, H.M., Fava, C., Thomas, D., Burger, J.A., Borthakur, G., Pate, O. Cortes, J. (2007) Imatinib dose can be safely reduced after complete cytogenetic response (CCyR) in patients (pts) with chronic myeloid leukemia (CML) in early chronic phase (CP) treated with high-dose imatinib [abstract]. Blood, 110. Abstract 1043.
15. Kantarjian, H., Talpaz, M., O'Brien, S., Garcia-Manero, G., Verstovsek, S., Giles, F., Rios, M.B., Shan, J., Letvak, L., Thomas, D., Faderl, S., Ferrajoli, A. Cortes, J. (2004) High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood, 103, 2873 2878. (Pubitemid 38451654)
16. Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O'Brien, S., Wassmann, B., Tanaka, C., Manley, P., Rae, P., Mietlowski, W., Bochinski, K., Hochhaus, A., Griffin, J.D., Hoelzer, D., Albitar, M., Dugan, M., Cortes, J., Alland, L. Ottmann, O.G. (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. New England Journal of Medicine, 354, 2542 2551. (Pubitemid 43882350)
17. Kantarjian, H.M., Giles, F., Gattermann, N., Bhalla, K., Alimena, G., Palandri, F., Ossenkoppele, G.J., Nicolini, F.E., O'Brien, S.G., Litzow, M., Bhatia, R., Cervantes, F., Haque, A., Shou, Y., Resta, D.J., Weitzman, A., Hochhaus, A. le Coutre, P. (2007) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood, 110, 3540 3546.
18. Kaplan, E.L. Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457 481.
19. Larson, R.A., Druker, B.J., Guilhot, F., O'Brien, S.G., Riviere, G.J., Krahnke, T., Gathmann, I. Wang, Y. (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood, 111, 4022 4028.
20. Manley, P.W., Mestan, J., Cowan-Jacob, S., Wartmann, M., Weisberg, E., Fabbro, D., Gilliland, D.G. Griffin, J.D. (2005) AMN107: inhibitory profile against non-mutated and mutated forms of the Bcr-Abl tyrosine kinase [abstract]. Proceedings of the American Association for Cancer Research, 46. Abstract 5985.
21. O'Brien, S.G., Guilhot, F., Goldman, J.M., Hochhaus, A., Hughes, T.P., Radich, J.P., Rudoltz, M., Filian, J., Gathmann, I., Druker, B.J. Larson, R.A. (2008) International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM) [abstract]. Blood, 112. Abstract 186.
22. O'Hare, T., Walters, D.K., Stoffregen, E.P., Jia, T., Manley, P.W., Mestan, J., Cowan-Jacob, S.W., Lee, F.Y., Heinrich, M.C., Deininger, M.W. Druker, B.J. (2005) In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Research, 65, 4500 4505.
23. Peng, B., Hayes, M., Resta, D., Racine-Poon, A., Druker, B.J., Talpaz, M., Sawyers, C.L., Rosamilia, M., Ford, J., Lloyd, P. Capdeville, R. (2004) Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. Journal of Clinical Oncology, 22, 935 942. (Pubitemid 41103606)
24. Saglio, G., Kim, D.-W., Issaragrisil, S., le Coutre, P.D., Reiffers, J., Lobo, C., Pasquini, R., Clark, R.E., Hughes, T.P., Hochhaus, A., Gallagher, N.J., Hoenekopp, A., Dong, M., Haque, A., Kantarjian, H.M. Larson, R.A. (2009) Nilotinib demonstrates superior efficacy compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase: results from the international randomized phase III ENESTnd trial [abstract]. Blood, 114. Abstract LBA-1.
25. Sawyers, C.L., Kantarjian, H., Shah, N., Cortes, J., Paquette, R., Donato, N., Nicoll, J., Bleickardt, E., Chen, T.T. Talpaz, M. (2005) Dasatinib (BMS-354825) in patients with chronic myeloid leukemia (CML) and philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to imatinib: update of a phase i study [abstract]. Blood, 106. Abstract 38.
26. Shah, N.P., Tran, C., Lee, F.Y., Chen, P., Norris, D. Sawyers, C.L. (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science, 305, 399 401.
27. Shah, N.P., Kantarjian, H.M., Kim, D.W., Rea, D., Dorlhiac-Llacer, P.E., Milone, J.H., Vela-Ojeda, J., Silver, R.T., Khoury, H.J., Charbonnier, A., Khoroshko, N., Paquette, R.L., Deininger, M., Collins, R.H., Otero, I., Hughes, T., Bleickardt, E., Strauss, L., Francis, S. Hochhaus, A. (2008) Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. Journal of Clinical Oncology, 26, 3204 3212.
28. Sneed, T.B., Kantarjian, H.M., Talpaz, M., O'Brien, S., Rios, M.B., Bekele, B.N., Zhou, X., Resta, D., Wierda, W., Faderl, S., Giles, F. Cortes, J.E. (2004) The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer, 100, 116 121. (Pubitemid 37553546)
29. Talpaz, M., Shah, N.P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., Blackwood-Chirchir, M.A., Iyer, V., Chen, T.T., Huang, F., Decillis, A.P. Sawyers, C.L. (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. New England Journal of Medicine, 354, 2531 2541. (Pubitemid 43882349)
30. Weisberg, E., Manley, P.W., Breitenstein, W., Bruggen, J., Cowan-Jacob, S.W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., Kung, A.L., Mestan, J., Daley, G.Q., Callahan, L., Catley, L., Cavazza, C., Azam, M., Neuberg, D., Wright, R.D., Gilliland, D.G. Griffin, J.D. (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell, 7, 129 141.
31. White, D.L., Saunders, V.A., Dang, P., Engler, J., Zannettino, A.C., Cambareri, A.C., Quinn, S.R., Manley, P.W. Hughes, T.P. (2006) OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood, 108, 697 704.
32. White, D.L., Saunders, V.A., Dang, P., Engler, J., Venables, A., Zrim, S., Zannettino, A., Lynch, K., Manley, P.W. Hughes, T. (2007) Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood, 110, 4064 4072.
33. White, D.L., Saunders, V.A., Dang, P., Frede, A., Eadie, L., Soverini, S., Quarantelli, F., Lin, P., Thornquist, M., Kim, D.-W., Pane, F., Martinelli, G., Radich, J., Kalebic, T., Saglio, G. Hughes, T. (2008) CML Patients with Low OCT-1 activity achieve better molecular responses on high dose imatinib than on standard dose. those with high OCT-1 activity have excellent responses on either dose: a TOPS correlative study [abstract]. Blood, 112. Abstract 3187.